Growth Hormone Release Studies
Same day / next business day dispatch
Free Shipping on orders over $200
Tesamorelin is a synthetic version of growth hormone releasing hormone, or GHRH. The sequence matches the full 44 amino acid human hormone. A chemical group added to one end protects it from an enzyme called DPP-4, which would otherwise break it down quickly. Research has measured growth hormone output and how fat tissue is distributed in study models.
Synthetic GHRH(1-44) analog (trans-3-hexenoic acid-modified)
The pathways Tesamorelin acts on — and what each one does. Signalling pathways studied in preclinical models · illustrative.
Tesamorelin is a synthetic trans-3-hexenoic acid–modified analog of human GHRH(1-44). It binds and activates pituitary GHRH receptors, stimulating endogenous growth hormone (GH) secretion while preserving normal pulsatile GH release patterns — unlike exogenous GH administration.
Clinical trials demonstrate tesamorelin reduces visceral adipose tissue (VAT) through GH-mediated lipolytic pathways. GH activates hormone-sensitive lipase in adipocytes, promoting free fatty acid release from visceral fat depots. This mechanism underlies its FDA-approved indication for HIV-related lipodystrophy.
Emerging research explores tesamorelin's effects on brain structure and function via IGF-1 signaling. Studies in older adults with mild cognitive impairment report changes in regional gray matter volume and functional connectivity. GH/IGF-1 axis modulation is hypothesized to support neuroplasticity mechanisms.
The main areas Tesamorelin is being studied for — and the study-reported figures behind them.
Phase III trials confirmed significant reductions in visceral adipose tissue in HIV+ adults with abdominal fat accumulation. Mechanism involves GH-driven lipolysis in visceral depots without disproportionate effects on subcutaneous fat.
Falutz et al. 2010
Randomized controlled trials in older adults with mild cognitive impairment report tesamorelin's effects on regional brain volume and cognitive performance, mediated through elevated IGF-1 signaling.
Baker et al. 2019
Research model for studying GHRH receptor pharmacology, GH secretagogue effects, and downstream IGF-1 modulation in the context of GH deficiency states and aging-related GH decline.
Stanley et al. 2011
Studies report tesamorelin's effects on triglycerides, non-HDL cholesterol, and carotid intima-media thickness in HIV-positive adults, supporting research into GH-axis modulation of cardiovascular risk markers.
Falutz et al. 2014
Representative figures from published research. Bars fill as you scroll.
Figures are representative of published research findings and shown for reference.
Every batch of Tesamorelin is sent to an accredited independent laboratory before it ships. Here is what we screen for.
| Chemical Name | Trans-3-hexenoic acid–GRF(1-44)-amide |
|---|---|
| Sequence | Modified GHRH(1-44) analog (44 amino acids) |
| Molecular Weight | 5135.8 Da |
| Molecular Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| COA | Included with every order |
Tesamorelin is a synthetic analog of human growth hormone–releasing hormone (GHRH), specifically a modified version of GHRH(1-44) with a trans-3-hexenoic acid group added to extend stability. Unlike exogenous growth hormone, tesamorelin stimulates the pituitary gland to produce its own GH, which preserves the natural pulsatile release pattern and provides physiological feedback regulation that exogenous GH bypasses entirely.
Yes. Tesamorelin is FDA-approved under the brand name Egrifta (approved 2010) for treatment of excess abdominal fat (lipodystrophy) in HIV-positive adults receiving antiretroviral therapy. This is the only approved indication. Research-grade tesamorelin sold here is for in vitro research purposes only and is not the approved pharmaceutical product.
Phase III clinical trials demonstrated approximately 15% reduction in visceral adipose tissue as measured by CT scan after 26 weeks of treatment in HIV-positive adults. The effect was attributed to GH-mediated activation of hormone-sensitive lipase specifically in visceral fat depots. Trunk fat area reduction averaged ~18% vs. placebo in the primary trials.
Emerging research is exploring tesamorelin's potential effects on brain structure and cognitive function via elevated IGF-1 signaling. A randomized controlled trial by Baker et al. (2019) in older adults with mild cognitive impairment reported changes in brain volume and verbal memory scores associated with 20-week tesamorelin treatment. This represents an active area of academic investigation.
In Phase III trials, common adverse events included injection site reactions, joint pain (arthralgia), water retention/edema, and glucose intolerance. Tesamorelin may increase IGF-1 to supranormal levels, which requires monitoring. It is contraindicated in active malignancy and during pregnancy. Long-term effects beyond 52 weeks in clinical use are still under study.
Lyophilized tesamorelin should be stored at -20°C and protected from moisture and light. The trans-3-hexenoic acid modification improves resistance to dipeptidyl peptidase IV (DPP-IV) cleavage compared to native GHRH, but the material should still be handled carefully to preserve biological activity.
Independent published research indexed from PubMed and peer-reviewed journals — not Zorva Lab claims.
For Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
Back to catalog